Ministry of Health has banned about 344 drugs fixed combinations of drugs, including cough syrups compositions, saying involving "risk" for humans and safer alternatives were available.
The drug prohibition takes effect
immediately and the ministry has come out with a newsletter reporting on the
issue.
"In total, 344 such fixed
dose combinations have been banned. We tried to objectivity to the subject by
roping at best scientists to study the effects.
"Show cause notices were
issued also to over 344 companies and given time to make other arrangements
after the expert committee gave its recommendations," said an official
from the Ministry of Health.
"Some of them do not even
want to answer. Everyone was given ample opportunity. After that, the movement
started. It is done after much consideration," the official said.
According to the notification,
the matter has been examined by an expert committee appointed by the central
government ministry of health.
"Based on the
recommendations of the expert committee, the Central Government is convinced
that it is all-important and adapted in the accessible interest to regulate
through the ban on the manufacture for sale, sale and distribution for human
use of such drugs in the country, "said the notice.
The 344 prohibited drugs include
fixed-dose combination of codeine syrup Chlopheniramine maleate and sold under
the popular brand cough syrup Corex.
Following the government ban,
major pharmaceutical Pfizer has discontinued the manufacture and sale of Corex
with immediate effect.
"This is to acquaint you
that the Government of India vide notification ... March 10, 2016 ... has
banned the manufacture for sale, sale and distribution of fixed-dose
combination of drugs maleate Chlopheniramine Syrup + codeine with immediate
effect.
"In appearance of this, the
company has decided to put an end to the manufacture and sale of its drug Corex
with immediate effect," Pfizer said in a BSE filing today.
Fixed dose combination are
combinations of two or more active drugs in a single dosage form.
0 comments:
Post a Comment